Anagliptin, a dipeptidyl peptidase-4 inhibitor, decreases macrophage infiltration and suppresses atherosclerosis in aortic and coronary arteries in cholesterol-fed rabbits
Authors:
- 1 June 2016
- journal article
- research article
- Published by Elsevier in Metabolism
- Vol. 65 (6) , 893-903
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Preventive Effect of Dipeptidyl Peptidase-4 Inhibitor on Atherosclerosis Is Mainly Attributable to Incretin's Actions in Nondiabetic and Diabetic Apolipoprotein E-Null MicePLOS ONE, 2013
- Soluble CD26/Dipeptidyl Peptidase IV Enhances the Transcription of IL-6 and TNF-α in THP-1 Cells and MonocytesPLOS ONE, 2013
- Glucose-Dependent Insulinotropic Polypeptide Prevents the Progression of Macrophage-Driven Atherosclerosis in Diabetic Apolipoprotein E-Null MicePLOS ONE, 2012
- Cardiovascular Biology of the Incretin SystemEndocrine Reviews, 2012
- Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and ChemotaxisCirculation, 2011
- DPP-4 (CD26) Inhibitor Alogliptin Inhibits Atherosclerosis in Diabetic Apolipoprotein E–Deficient MiceJournal of Cardiovascular Pharmacology, 2011
- Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout miceDiabetologia, 2011
- Dipeptidyl Peptidase 4 Is a Novel Adipokine Potentially Linking Obesity to the Metabolic SyndromeDiabetes, 2011
- Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trialsThe Lancet, 2010
- Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4Diabetes, 2010